DNA Sequencing: Emerging Technologies and Applications
- May 2016
- 357 pages
- Report ID: 254559
Use this report to:
Analyze the next-generation sequencing industry and market, as well as Sanger and emerging sequencing.
Explore strong growth opportunities including benchtop and handheld sequencing instruments, clinical diagnostics and applied sequencing services, etc.
Discuss sequencing technologies, market applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies.
Evaluate key industry trends and company activities, as well as market dynamics.
The global market for sequencing products has grown to $5.9 billion in 2015 from $5.3 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 18.7% from 2015 to 2020, reaching nearly $13.8 billion by 2020.
The market for sequencing instruments, reagents and consumables in the sequencing industry is expected to grow from $3.0 billion in 2015 to $4.7 billion in 2020, increasing at a CAGR of 9.5% for the period 2015-2020.
The global market for sequencing services in the sequencing industry is expected to grow from $2.9 billion in 2015 to $9.1 billion in 2020, increasing at a CAGR of 26.0% for the period 2015-2020.
STUDY GOALS AND OBJECTIVES
BCC Research’s goal for this study is to provide an in-depth analysis of the sequencing industry, an important industry in life sciences with enormous market potential. The approach for analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key applications (e.g., research, applied, services, sample prep, informatics) in which sequencing will have market share by 2020.
BCC Research examines the markets for sequencing products and services for the years 2014, 2015 and 2020.
Emphasis is placed on the global next-generation sequencing (NGS) diagnostic markets, which are characterized and quantified by disease indication, test complexity, test purpose and geography.
Sequencing market segments that provide strong growth opportunities include benchtop and handheld sequencing instruments; clinical diagnostics (e.g., oncology, transplant, reproductive health); and applied sequencing services (e.g., agriculture, consumer, forensics).
The report provides a comprehensive discussion of sequencing technologies, market applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for accessing sequencing industry opportunities.
REASONS FOR DOING THE STUDY
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome.
The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).
Beginning in 2005, the launch of next-generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications.
The costs of sequencing have rapidly dropped to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests.
As a result, opportunities for sequencing products and services are emerging in diverse applications ranging, for example, from clinical diagnostics to agriculture genetic testing markets.
The clinical value of sequencing has been shown for many applications, and several launched tests are having commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. New product formats, including liquid biopsy and single cell sequencing, are being introduced.
At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential.
The continuing emphasis in the industry on precision medicine is helping to pave the way for sequencing systems. Examples of this include the Precision Medicine Program in the U.S., which will sequence more than one million people to identify genomic drivers of cancer, and the recent declaration of precision medicine as a focus for China’s 13 Five Year Plan for 2016 to 2020.
These technical and market factors are driving this market, so that it is now timely to re-examine the sequencing markets with this updated report.